NUBEQA
300MG TBL FLM 112
| Maximum ex-factory price/Ex-factory price ? | 73650,61 CZK |
|---|---|
| Legal basis of maximum ex-factory price/ex-factory price ? | Maximum ex-factory price set by the law. |
Informace o základní úhradě
| Core reimbursement from health insurance ? | 76834,05 CZK |
|---|---|
| Maximum reimbursement from health insurance ? | 87151,60 CZK |
| Legal basis of reimbursement from health insurance ? | Reimbursement set by the law. |
| Indication restriction of reimbursement ? | Darolutamid je hrazen u pacientů s nemetastatickým, kastračně rezistentním karcinomem prostaty ve vysokém riziku rozvoje metastáz, s dobou do zdvojení hladiny PSA menší nebo rovno 10 měsíců. Jedná se o pacienty se stavem výkonnosti 0-1 dle ECOG, kontinuálně léčené androgen-deprivační terapií (LHRH analogy nebo po orchiektomii). Terapie je hrazena do progrese onemocnění nebo do rozvoje nepřijatelných projevů toxicity. |
| Prescribing doctor's specialisation ? | – |
| Reporting limit ? | S: If it is advisable to concentrate the use of a product in specialist facilities under Section 15(10) of the Act in the public interest, the decision shall allocate the "S" symbol to these products. These products may be charged to the health insurer as a separately charged product solely by specialist facilities under an agreement concluded with the health insurer. |
| Rough price for the final consumer ? | 83579,78 CZK |
| Rough payment for the final consumer (for 1 prescribed package dispensed) ? | 0 CZK |
| Eligible extra payment ? | – |
| Eligible extra payment for individuals aged 65 and older ? | – |
cz